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Background: A steady decline in gastric cancer mortality rate over the last few decades is observed in Western Europe.
However it is still not clear if this trend applies to Eastern Europe where high incidence rate of gastric cancer is observed.
Methods: This was a retrospective non-randomized, single center, cohort study. During the study period 557
consecutive patients diagnosed with gastric cancer in which curative operation was performed met the inclusion criteria.
The study population was divided into two groups according to two equal time periods: 01-01-1994 – 31-12-2000
(Group I – 273 patients) and 01-01-2001 – 31-12-2007 (Group II – 284 patients). Primary (five-year survival rate) and
secondary (postoperative complications, 30-day mortality rate and length of hospital stay) endpoints were evaluated
and compared.
Results: Rate of postoperative complications was similar between the groups, except for Grade III (Clavien-Dindo
grading system for the classification of surgical complications) complications that were observed at significantly lower
rates in Group II (26 (9.5%) vs. 11 (3.9%), p = 0.02). Length of hospital stay was significantly (p = 0.001) shorter (22.6 ± 28.9
vs. 16.2 ± 17.01 days) and 30-day mortality was significantly (p = 0.02) lower (15 (5.5%) vs. 4 (1.4%)) in Group II. Similar
rates of gastric cancer related mortality were observed in both groups (92.3% vs. 90.7%). However survival analysis
revealed significantly (p = 0.02) better overall 5-year survival rate in Group II (35.6%, 101 of 284) than in Group I
(23.4%, 64 of 273). There was no difference in 5-year survival rate when comparing different TNM stages.
Conclusions: Gastric cancer treatment results remain poor despite decreasing early postoperative mortality rates,
shortening hospital stay and improved overall survival over the time. Prognosis of treatment of gastric cancer
depends mainly on the stage of the disease. Absence of screening programs and lack of clinical symptoms in early
stages of gastric cancer lead to circumstances when most of the patients presenting with advanced stage of the
disease can expect a median survival of less than 30 months even after surgery with curative intent.
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Although a steady decline in gastric cancer mortality
rates over the last few decades is observed, gastric can-
cer still remains the fourth most common cancer and is
the second leading cause of cancer death worldwide with
poor survival rates [1]. While incidence rates of gastric
cancer in North America, Africa, South and West Asia* Correspondence: a_mickevicius@yahoo.com
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article, unless otherwise stated.are declining, rates in North-East Asia, Eastern part of
South America and Eastern Europe stay high [1-3]. Sur-
gery remains the major and potentially curative treat-
ment method for resectable gastric cancer. Considering
the location and size of the tumor as well as invasion to
the adjacent organs, routinely standard radical total or
subtotal gastrectomy with lymphadenectomy or multior-
gan resections are performed [4-6]. The overall 5-year
survival rate of patients with advanced resectable gastric
cancer differs between different countries and different
centres, but in general it ranges from 10% to 30% [5,7,8].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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liver metastasis, disease stage and tumour size are im-
portant predictive factors for survival in patients with re-
sectable gastric cancer [9-11]. However it is not certainly
clear if these predictive factors are the same in all re-
gions and why incidence rates of gastric cancer are still
high in the region of Eastern Europe.
The aim of this single centre study was to compare
the clinical course and outcomes, such as postoperative
complications, the length of hospital stay and mortality
rate, over two distinctive time periods.
Methods
This was a retrospective non-randomized, single center,
cohort study. Data collection was performed at the Depart-
ment of Surgery, Lithuanian University of Health Sciences
using specially developed and maintained database from
01-01-1994 to 31-12-2007. During this period 708 patients
underwent radical gastrectomy. Five hundred fifty seven
consecutive patients were included in the study according
to the following inclusion criteria: (1) histologically proven
gastric adenocarcinoma; (2) diagnosis based on the UICC
TNM staging classification; (3) curative D1 or D2 gastrec-
tomy performed; (4) available complete medical record; (5)
postoperative follow-up. Patients with proven distant meta-
static disease and in whom only palliative surgery was
performed, were excluded from the study. The study popu-
lation was divided in two groups according to two equal
time periods: 01-01-1994 – 31-12-2000 (Group I – 273
patients) and 01-01-2001 – 31-12-2007 (Group II – 284
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Figure 1 Patient’s distribution between groups and subgroups.with gastric cancer were treated according to the guidelines
of that time. Standardized protocol was introduced in
the year 2001: preoperative evaluation and care (preopera-
tive computed tomography (CT) staging, prophylactic
antibiotics), surgical treatment and postoperative care
(prophylaxis of thromboembolic disorders; early mobilisa-
tion; on day 2 after surgery patients were allowed to drink
clear liquids; on postoperative day 3 the soft diet was
allowed; drain’s placement was at the discretion of the sur-
geon). The Kaunas Regional Biomedical Research Ethics
Committee approved the study (protocol no. BE-2-10) and
allowed the use of publicly unavailable database. All pa-
tients provided written informed consent. The primary
outcome was measured as the five-year survival rate. The
gastric cancer- related survival, rates of postoperative com-
plications, the length of hospital stay and 30-day mortality
rate were considered as secondary outcomes. The out-
comes were studied to evaluate the progress in gastric can-
cer treatment results over time.
Surgical procedure
All the surgical procedures were based on the intention
to cure. The extent of the surgical procedure was
planned based on pre-operative and intra-operative find-
ings, physical condition of the patient. Considering the
location of the tumor, routinely standard total (adeno-
carcinoma involving the proximal third of the stomach)
or subtotal (adenocarcinoma of the distal and middle
thirds of the stomach) gastrectomy with D1 or D2
lymphadenectomy and a Roux-en-Y reconstruction was






related deaths 101 alive
17 deaths due to 
other diseases
Table 2 Staging of the disease
Parameter Group I Group II P value
Pathological stage
T1 21 (7.7%) 39 (13.7%) 0.042
T2 42 (15.4%) 101 (35.6%) 0.0001
T3 118 (43.2%) 116 (40.8%) 0.775
T4 92 (33.7%) 28 (9.9%) 0.0001
N stage
N0 86 (31.5%) 91 (32.0%) 0.931
N1 68 (24.9%) 87 (30.6%) 0.276
N2 92 (33.7%) 73 (25.7%) 0.133
N3 27 (9.9%) 33 (11.6%) 0.589
TNM Stage
IA 18 (6.6%) 30 (10.6%) 0.135
IB 30 (11.0%) 47 (16.5%) 0.114
IIA 43 (15.8%) 61 (21.5%) 0.165
IIB 51 (18.7%) 47 (16.5%) 0.586
IIIA 58 (21.2%) 65 (22.9%) 0.765
IIIB 51 (18.7%) 24 (8.5%) 0.002
IIIC 22 (8.1%) 10 (3.5%) 0.044
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of Gastric Carcinoma [12]. Combined multiorgan resec-
tions were performed in cases of advanced tumors in-
volving the pancreas, colon or spleen. Surgery was
considered as a curative when there was no macroscop-
ically residual tumor after surgery and resection margins
were histologically clear (R0).
Postoperative course
Postoperative complications were classified according
Clavien-Dindo grading system for the classification of
surgical complications (Grade I - V) [13].
Different mainly fluorouracil (5-FU) based adjuvant
chemotherapy regiments were inconsistently used postop-
eratively in the period from 1994 to 2000. Whereas patients
during the period from 2001 to 2007 as a standard received
a combined 5-FU and leucovorin adjuvant chemotherapy
or concurrent chemoradion treatment (5-FU and leu-
covorin with 45 Gy radiation dose) in more advanced
cancer cases.
Statistical analysis
Statistical analysis was performed using SPSS 14.0 for
Windows (SPSS Inc., Chicago, USA). The data are pre-
sented as mean ± Standard deviation or median and
range. The cumulative survival was determined by the
Kaplan-Meier method, and univariate comparisons be-
tween the groups were performed using the log-rank
test. The independent prognostic factors were examined
by Cox regression analysis. For comparison between
groups, the Mann–Whitney test or Student’s t test were
employed where appropriate. P < 0.05 was considered
statistically significant.
Results
Seven hundred and eight patients with proven gastric
adenocarcinoma underwent a subtotal or total gastrectomyTable 1 Patients’ characteristics
Parameter Group I Group II P value
Gender
Male 155 (56.8%) 164 (57.7%) 0.944
Female 118 (43.2%) 120 (42.3%) 0.938
Age 63.2 ± 12.7 64.3 ± 12.1 0.331
≤ 65 135 (49.5%) 134 (47.2%) 0.767
> 65 138 (50.5%) 150 (52.8%) 0.772
Procedure
Total gastrectomy 80 (29.3%) 52 (18.3%) 0.019
Subtotal gastrectomy 193 (70.7%) 232 (81.7%) 0.273
D1 lymphadenectomy 7 (2.6%) 5 (1.8%) 0.572
D2 lymphadenectomy 266 (97.4%) 279 (98.2%) 0.952
Total 273 284and D1 or D2 lymphadenectomy with curative intent be-
tween 1994 and 2007. One hundred fifty one patients were
unavailable for 5 years follow-up. The most frequent de-
tected reason of the unavailability was moving abroad.
Data from 557 patients which were followed-up postopera-
tively was analysed. The distribution of patients between
groups and subgroups is shown in Figure 1. There were no
significant differences between the groups in gender and
age. The number of elderly (>65 years) patients was also
similar (50.5% vs. 52.8%). Total gastrectomy was statisti-
cally significantly more often performed in Group I (29.3%)
than in Group II (18.3%). D2 lymphadenectomy was more
often performed than D1 lymphadenectomy in both
groups (Table 1). Gastric cancer in early stages (IA - IIA)Table 3 Postoperative course and outcomes
Parameter Group I Group II P value
Hospital stay (days) 22.61 ± 28.96 16.20 ± 17.01 0.001
Complications* 55 (20.1%) 42 (14.8%) 0.187
I 13 (4.7%) 15 (5.4%) 0.848
II 8 (2.9%) 6 (2.1%) 0.598
III 26 (9.5%) 11 (3.9%) 0.017
IV 4 (1.5%) 5 (1.7%) 1.000
V 4 (1.5%) 5 (1.7%) 1.000
30-day mortality 15 (5.5%) 4 (1.4%) 0.017
*- According to Clavien-Dindo grading system for the classification of surgical
complications.
Table 4 Postoperative survival analysis
Parameter Group I Group II P value
Overall survival (months) 48.40+/−65,966 43.78+/− 39.736 0.319
1-year survival rate 137 (50.2%) 203 (71.5%) 0.013
2-years survival rate 110 (40.3%) 150 (52.8%) 0.083
5-year survival rate 64 (23.4%) 101 (35.6%) 0.021
IA 11 (61.1%) 25 (83.3%) 0.644
IB 22 (73.3%) 33 (70.2%) 1.000
IIA 17 (39.5%) 23 (37.7%) 1.000
IIB 7 (13.7%) 13 (27.7%) 0.221
IIIA 7 (12.1%) 5 (7.7%) 0.552
IIIB 0 2 (8.3%) 0.111
IIIC 0 0 -
Deaths 209 (76.6%) 183 (64.4%) 0.210
Gastric cancer related 193 (92.3%) 166 (90.7%) 0.942
Other causes 16 (7.7%) 17 (9.3%) 0.717
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I and in late stages (IIB - IIIC) more frequently in Group I.
Statistically significant difference was found only when
comparing stages IIIB-IIIC. Significantly more patients
were diagnosed with lower stage of the primary tumorFigure 2 Overall survival (in months) after surgery according to TNM(T stage) in Group II (13.7% vs 7.7% in T1 stage (P = 0.04)
and 35.6% vs 15.4% in T2 stage (P = 0.0001)). On the con-
trary in Group I more patients were diagnosed in T4 stage
(33.7% vs 9.9%, P = 0.0001) (Table 2).
When analyzing postoperative course of the disease
shorter hospital stay (16.20 ± 17.01 vs. 22.61 ± 28.96 days,
P = 0.001) and lower 30-day mortality rate (1.4% vs 5.5%,
P = 0.0173) was identified in Group II. During postopera-
tive period in 6 patients (2.2%) of Group I and in 7 patients
(2.5%) of Group II anastomotic leakage was identified.
However grade of postoperative complications was similar
between both groups. Only Grade III (Complications re-
quiring surgical, endoscopic or radiological intervention)
complications were statistically significant more often iden-
tified in Group I (9.5% vs 3.9%, P = 0.017) (Table 3).
The survival analysis revealed higher median overall
survival (months) in Group I (48.40 ± 65.966 vs. 43.78 ±
39.736). However Group I patients are observed for a
longer time period and long-term survivors among them
could influence this outcome. In contrary when analys-
ing 1-year and 5-year survival rates, significantly higher
survival is observed in Group II (71.5% vs. 50.2% and
35.6% vs. 23.4%). Patients with more advanced T stage
and involved lymphnodes had worse 5-year survival
prognosis as compared with patients with les advancedstage (Group I).
Mickevicius et al. BMC Surgery 2014, 14:98 Page 5 of 7
http://www.biomedcentral.com/1471-2482/14/98T stage and no lymphnodes involvement. However sta-
tistically significant difference was found only when ana-
lyzing lymphnodes involvement (p < 0.05).
In both groups the reasons of death were similar; the
majority of patients died of gastric cancer (92.3% vs.
90.7%). There was no difference in 5-year survival rate
when comparing different TNM stages between both
groups (Table 4). However in early stages (IA - IIA) sur-
vival rate was higher comparing with advanced stages
(IIB - IIIC) (Figures 2 and 3).
Discussions
The incidence of gastric cancer in Eastern Europe re-
mains high following Eastern Asia and South America.
The highest gastric cancer incidence rate in European
Union (EU) is reported in Lithuania [14]. In this single-
institutional study we present case series from large uni-
versity hospital in Lithuania raising a question: is there a
significant progress in terms of treatment success and
survival among patients diagnosed with gastric cancer
and treated with curative surgery over time? To clarify
changes, positive or negative tendencies the two groups
on background of time of surgery were created.
Most of demographic data, clinicopathologic character-
istics in our study are comparable to the groups presentedFigure 3 Overall survival (in months) after surgery according to TNMfrom other European countries. Regrettably, gastric cancer
remains often diagnosed in advanced stages in Lithuania,
leading to poor prognosis. Late diagnosis of gastric cancer
is a well-known problem among patients from Western
countries. Hundahl et al. [7] from United States (US) re-
port 65% of gastric cancers presenting at an advanced
stage (T3-T4) with a nearly 85% of tumours accompanied
with lymph node affection at the time of surgery. The data
are very close to ours (T3-T4 - 63.6%; N+ 68.2%). How-
ever higher gastric cancer incidence rate in Lithuania leads
to even more actual problem.
The interesting difference identified between our data
and studies done in Western Europe - a lack of growing
incidence of upper-third gastric cancer. In contrary, we
even had more distal and middle third tumours and
higher proportion of patients underwent subtotal gas-
trectomy in Group II. Although we have not analysed
this factor in our study, high prevalence of Helicobacter
pylori infection in Lithuania (78.5% in the year 1999 and
69.7% in the year 2005) could be related to the high inci-
dence of gastric cancer [15].
The overall incidence of directly surgery-related postop-
erative complications in our study (anastomosis or duo-
denal stump leakage) <3% is comparable to majority of
published data [16-18]. The rate and grade of postoperativestage (Group II).
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study was similar in both groups; however 30-day mortal-
ity rate and in-hospital stay decreased significantly in
Group II. These results should be considered as a conse-
quence of more detailed preoperative patients’ selection,
standardised surgery technique, and improved periopera-
tive care over time.
The overall 5-year survival rate was slightly higher in
Group II, however remaining below 40% in entire cohort.
The higher survival rate possibly caused by a higher rate
of early detection (standardized protocol of diagnosis) of
gastric cancer (more T1, T2 tumours, less IIIB, IIIC stages
in Group II), perioperative care improvement over time
and possibilities of palliation procedures in cases of recur-
rent disease. The most common cause of treatment failure
in our study was peritoneal recurrence and spread of
the disease. Similar data are presented by other authors
[19,20]. Observed 5-year survival rate in early stages (IA
61.1% vs. 83.3% and IB 73.3% vs. 70.2%) of gastric cancer
is lower than in Eastern countries, but is similar to the
data presented by the Western European countries from
the similar time period [21,22].
Regarding the surgical technique and extent of lymph
node dissection, it became highly standardised over last
15 years. The patients in our study mainly underwent gas-
trectomy with a Roux-en-Y reconstruction and D2 lymph-
adenectomy (97.4% vs. 98.2%). There has been controversy
regarding the extent of lymph node dissection around the
European centres in last decade, pointing on higher post-
operative morbidity after D2 dissection, however most ex-
perts suggest that extended lymphadenectomy could be
performed with acceptable morbidity and mortality rate by
specialized surgeons in large-volume centres [23-25].
Conclusions
Despite some positive changes in early postoperative mor-
tality rate, hospital stay and overall survival over the time,
gastric cancer treatment results remain poor. Prognosis of
treatment of gastric cancer depends mainly on the stage of
the disease. Absence of screening programs and lack of
clinical symptoms in early stages of gastric cancer lead to
circumstances when most of the patients presenting with
advanced stage of the disease can expect a median survival
of less than 30 months even after curative intent surgery.
The most efficient way to reach more significant progress
in gastric cancer treatment should concentrate mostly on
earlier diagnosis, when survival results after radical sur-
gery are far more promising.
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